Symbols / CATX $4.51 +0.00% Perspective Therapeutics, Inc.

Healthcare • Medical Devices • United States • ASE
CATX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Johan M. Spoor
Exch · Country ASE · United States
Market Cap 514.22M
Enterprise Value 372.36M
Income -103.64M
Sales 884.00K
FCF (ttm) -60.37M
Book/sh 2.79
Cash/sh 1.27
Employees 163
Insider 10d —
IPO Nov 10, 2005
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.84
PEG —
P/S 581.70
P/B 1.62
P/C —
EV/EBITDA -3.38
EV/Sales 421.22
Quick Ratio 5.08
Current Ratio 5.17
Debt/Eq 1.57
LT Debt/Eq —
EPS (ttm) -1.41
EPS next Y -1.17
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-16
ROA -23.34%
ROE -41.65%
ROIC —
Gross Margin 0.00%
Oper. Margin -926.33%
Profit Margin 0.00%
Shs Outstand 114.02M
Shs Float 74.26M
Insider Own 10.81%
Instit Own 54.41%
Short Float 14.32%
Short Ratio 9.72
Short Interest 13.67M
52W High 6.16
vs 52W High -26.79%
52W Low 1.96
vs 52W Low 130.10%
Beta 1.87
Impl. Vol. 3.36%
Rel Volume 0.42
Avg Volume 3.42M
Volume 1.42M
Target (mean) $13.00
Tgt Median $13.00
Tgt Low $7.00
Tgt High $18.00
# Analysts 15
Recom Strong_buy
Prev Close $4.51
Price $4.51
Change 0.00%
About

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$13.00
Mean price target
2. Current target
$4.51
Latest analyst target
3. DCF / Fair value
$-9.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.51
Low
$7.00
High
$18.00
Mean
$13.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 reit Wedbush Outperform → Outperform $11
2026-03-23 main HC Wainwright & Co. Buy → Buy $13
2026-03-18 main B. Riley Securities Buy → Buy $13
2026-03-18 main UBS Buy → Buy $8
2026-03-18 reit Wedbush Outperform → Outperform $11
2026-03-17 main RBC Capital Outperform → Outperform $14
2026-03-17 reit BTIG Buy → Buy $14
2026-02-19 init Piper Sandler — → Overweight $16
2026-01-30 main HC Wainwright & Co. Buy → Buy $12
2026-01-30 reit Wedbush Outperform → Outperform $11
2026-01-13 reit BTIG Buy → Buy $14
2025-11-21 main UBS Buy → Buy $7
2025-11-18 main B. Riley Securities Buy → Buy $11
2025-10-13 reit BTIG Buy → Buy $14
2025-10-10 init BTIG — → Buy $14
2025-10-03 reit HC Wainwright & Co. Buy → Buy $10
2025-09-19 reit HC Wainwright & Co. Buy → Buy $10
2025-06-23 main B. Riley Securities Buy → Buy $12
2025-06-23 reit Wedbush Outperform → Outperform $11
2025-06-03 main RBC Capital Outperform → Outperform $16
News
RSS: Latest CATX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-13 HUNT JONATHAN ROBERT Officer — 11,000 $2.03 $22,295
2025-11-12 WILLIAMSON ROBERT F III Director — 9,498 $2.10 $19,946
2025-03-31 WOODS LORI A. Director — 23,475 $2.13 $49,999
2025-03-31 WILLIAMSON ROBERT F III Director — 60,337 $2.14 $132,151
2025-03-28 SPOOR JOHAN M Chief Executive Officer — 26,676 $2.21 $59,673
2025-03-28 GRAHAM JUAN Chief Financial Officer — 33,333 $2.25 $74,946
2024-12-04 HENSON HEIDI Director — 25,975 $3.85 $100,004
2024-12-04 SPOOR JOHAN M Chief Executive Officer — 8,000 $3.77 $30,132
2024-11-25 HUNT JONATHAN ROBERT Chief Financial Officer — 12,829 $3.55 $48,974
2024-11-25 WILLIAMSON ROBERT F III Director — 6,266 $3.62 $22,814
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-06-30
Total Revenue
0.00
0.00
0.00
-100.00%
10.79
Operating Revenue
0.00
0.00
0.00
-100.00%
10.79
Cost Of Revenue
—
—
—
6.18
Reconciled Cost Of Revenue
—
—
—
6.18
Gross Profit
—
—
—
4.62
Operating Expense
113.56
+70.01%
66.80
+63.15%
40.94
+240.98%
12.01
Research And Development
84.22
+102.26%
41.64
+95.38%
21.31
+725.37%
2.58
Selling General And Administration
30.23
+13.60%
26.61
+26.34%
21.06
+123.49%
9.43
Selling And Marketing Expense
—
—
—
2.76
General And Administrative Expense
30.23
+13.60%
26.61
+26.34%
21.06
+215.90%
6.67
Salaries And Wages
—
—
—
0.76
Other Gand A
30.23
+13.60%
26.61
+26.34%
21.06
+256.71%
5.91
Other Operating Expenses
-0.88
+39.20%
-1.45
-1.39%
-1.43
—
Total Expenses
113.56
+70.01%
66.80
+63.15%
40.94
+125.12%
18.19
Operating Income
-113.56
-70.01%
-66.80
-63.15%
-40.94
-453.93%
-7.39
Total Operating Income As Reported
-113.56
-24.95%
-90.89
-121.99%
-40.94
-453.93%
-7.39
EBITDA
-100.80
-29.11%
-78.07
-99.99%
-39.04
-446.52%
-7.14
Normalized EBITDA
-100.80
-86.72%
-53.98
-38.29%
-39.04
-446.52%
-7.14
Reconciled Depreciation
3.25
+40.98%
2.31
+133.87%
0.99
+297.58%
0.25
EBIT
-104.05
-29.45%
-80.38
-100.83%
-40.02
-441.52%
-7.39
Total Unusual Items
0.00
+100.00%
-24.09
0.00
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-24.09
0.00
0.00
Special Income Charges
0.00
+100.00%
-24.09
0.00
0.00
Impairment Of Capital Assets
0.00
-100.00%
24.06
0.00
—
Net Income
-103.12
-30.07%
-79.28
-70.46%
-46.51
-539.55%
-7.27
Pretax Income
-104.43
-29.84%
-80.43
-100.54%
-40.11
-451.51%
-7.27
Net Non Operating Interest Income Expense
7.74
-26.07%
10.47
+1128.52%
0.85
+615.97%
0.12
Interest Expense Non Operating
0.38
+683.33%
0.05
-41.46%
0.08
—
Net Interest Income
7.74
-26.07%
10.47
+1128.52%
0.85
+615.97%
0.12
Interest Expense
0.38
+683.33%
0.05
-41.46%
0.08
—
Interest Income Non Operating
8.11
-22.83%
10.52
+1025.80%
0.93
+684.87%
0.12
Interest Income
8.11
-22.83%
10.52
+1025.80%
0.93
+684.87%
0.12
Other Income Expense
1.40
+105.80%
-24.10
-141647.06%
-0.02
—
Other Non Operating Income Expenses
1.40
—
0.00
—
Tax Provision
-0.79
+62.18%
-2.10
+20.90%
-2.65
—
Tax Rate For Calcs
0.00
-69.23%
0.00
-60.67%
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.63
0.00
0.00
Net Income Including Noncontrolling Interests
-103.12
-30.07%
-79.28
-70.46%
-46.51
-539.55%
-7.27
Net Income From Continuing Operation Net Minority Interest
-103.64
-32.31%
-78.33
-109.13%
-37.45
-415.06%
-7.27
Net Income From Continuing And Discontinued Operation
-103.12
-30.07%
-79.28
-70.46%
-46.51
-539.55%
-7.27
Net Income Continuous Operations
-103.64
-32.31%
-78.33
-109.13%
-37.45
-415.06%
-7.27
Net Income Discontinuous Operations
0.51
+154.16%
-0.95
+89.52%
-9.05
—
Normalized Income
-103.64
-88.88%
-54.87
-46.49%
-37.45
-415.06%
-7.27
Net Income Common Stockholders
-103.12
-30.07%
-79.28
-70.46%
-46.51
-539.55%
-7.27
Diluted EPS
-1.40
-13.82%
-1.23
+29.31%
-1.74
-248.00%
-0.50
Basic EPS
-1.40
-13.82%
-1.23
+29.31%
-1.74
-248.00%
-0.50
Basic Average Shares
73.81
+14.57%
64.42
+140.72%
26.76
+88.50%
14.20
Diluted Average Shares
73.81
+14.57%
64.42
+140.72%
26.76
+88.50%
14.20
Diluted NI Availto Com Stockholders
-103.12
-30.07%
-79.28
-70.46%
-46.51
-539.55%
-7.27
Earnings From Equity Interest
-0.00
+75.00%
-0.01
+52.94%
-0.02
—
Gain On Sale Of PPE
0.00
+100.00%
-0.03
0.00
0.00
Preferred Stock Dividends
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
97.89
Current Assets
16.84
Cash Cash Equivalents And Short Term Investments
9.24
Cash And Cash Equivalents
9.24
Other Short Term Investments
0.00
Receivables
1.18
Accounts Receivable
1.17
Gross Accounts Receivable
1.81
Allowance For Doubtful Accounts Receivable
-0.65
Other Receivables
0.01
Accrued Interest Receivable
0.00
Inventory
—
Raw Materials
—
Work In Process
—
Finished Goods
—
Prepaid Assets
1.08
Assets Held For Sale Current
5.30
Other Current Assets
0.04
Total Non Current Assets
81.05
Net PPE
6.32
Gross PPE
6.99
Accumulated Depreciation
-0.67
Properties
0.00
Land And Improvements
1.28
Buildings And Improvements
1.77
Other Properties
3.76
Leases
0.18
Goodwill And Other Intangible Assets
74.42
Goodwill
24.06
Other Intangible Assets
50.35
Investments And Advances
0.13
Long Term Equity Investment
0.13
Non Current Prepaid Assets
0.00
Other Non Current Assets
0.18
Total Liabilities Net Minority Interest
22.71
Current Liabilities
15.66
Payables And Accrued Expenses
6.91
Payables
6.91
Accounts Payable
6.91
Current Accrued Expenses
3.93
Pensionand Other Post Retirement Benefit Plans Current
3.59
Current Debt And Capital Lease Obligation
0.10
Current Debt
0.05
Other Current Borrowings
0.05
Current Capital Lease Obligation
0.05
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
5.07
Total Non Current Liabilities Net Minority Interest
7.05
Liabilities Heldfor Sale Non Current
0.00
Long Term Debt And Capital Lease Obligation
2.46
Long Term Debt
1.68
Long Term Capital Lease Obligation
0.78
Long Term Provisions
—
Non Current Deferred Liabilities
4.59
Non Current Deferred Revenue
0.00
Non Current Deferred Taxes Liabilities
4.59
Other Non Current Liabilities
—
Stockholders Equity
75.18
Common Stock Equity
75.18
Capital Stock
0.03
Common Stock
0.03
Preferred Stock
0.00
Share Issued
28.18
Ordinary Shares Number
28.18
Treasury Shares Number
0.00
Additional Paid In Capital
227.59
Retained Earnings
-152.44
Gains Losses Not Affecting Retained Earnings
0.00
Treasury Stock
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
75.18
Total Capitalization
76.86
Working Capital
1.17
Invested Capital
76.90
Total Debt
2.55
Capital Lease Obligations
0.83
Net Tangible Assets
0.76
Tangible Book Value
0.76
Non Current Accrued Expenses
—
Notes Receivable
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-06-30
Operating Cash Flow
-82.48
-350.88%
-18.29
+50.44%
-36.91
-378.77%
-7.71
Cash Flow From Continuing Operating Activities
-82.48
-350.88%
-18.29
+50.44%
-36.91
-378.77%
-7.71
Net Income From Continuing Operations
-103.12
-30.07%
-79.28
-70.46%
-46.51
-539.55%
-7.27
Depreciation Amortization Depletion
3.25
+40.98%
2.31
+133.87%
0.99
+297.58%
0.25
Depreciation
3.25
+40.98%
2.31
+133.87%
0.99
+297.58%
0.25
Amortization Cash Flow
—
—
—
0.04
Depreciation And Amortization
3.25
+40.98%
2.31
+133.87%
0.99
+297.58%
0.25
Amortization Of Intangibles
—
—
—
0.04
Other Non Cash Items
0.01
-94.95%
0.10
-97.84%
4.58
+5848.05%
0.08
Stock Based Compensation
8.97
+66.44%
5.39
+44.11%
3.74
+243.88%
1.09
Provisionand Write Offof Assets
—
—
0.62
—
Asset Impairment Charge
10.00
-58.44%
24.06
0.00
—
Deferred Tax
-0.79
+62.18%
-2.10
+20.90%
-2.65
—
Deferred Income Tax
-0.79
+62.18%
-2.10
+20.90%
-2.65
—
Operating Gains Losses
0.25
+1090.48%
0.02
-4.55%
0.02
—
Net Foreign Currency Exchange Gain Loss
0.25
+484.62%
-0.07
—
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.03
+22.73%
0.02
0.00
Change In Working Capital
1.68
-94.72%
31.81
+989.52%
2.92
+257.84%
-1.85
Change In Receivables
-0.03
-118.93%
0.17
-14.65%
0.20
-51.11%
0.41
Changes In Account Receivables
0.11
-89.51%
1.05
+429.80%
0.20
—
Change In Inventory
0.00
-100.00%
0.01
-96.94%
0.36
+113.43%
-2.67
Change In Prepaid Assets
0.62
+132.65%
-1.91
-488.00%
-0.33
-806.52%
0.05
Change In Payables And Accrued Expense
2.16
-60.69%
5.49
+104.24%
2.69
+622.58%
0.37
Change In Accrued Expense
2.01
-44.14%
3.60
+222.87%
1.11
+719.85%
0.14
Change In Payable
0.15
-92.22%
1.89
+20.15%
1.57
+566.53%
0.24
Change In Account Payable
0.15
-92.22%
1.89
+20.15%
1.57
+566.53%
0.24
Change In Other Working Capital
-1.40
-105.00%
28.00
—
—
Change In Other Current Liabilities
0.33
+501.82%
0.06
0.00
—
Investing Cash Flow
41.23
+118.83%
-218.93
-998.25%
24.37
+8682.04%
-0.28
Cash Flow From Continuing Investing Activities
41.23
+118.83%
-218.93
-998.25%
24.37
+8682.04%
-0.28
Net PPE Purchase And Sale
-12.75
+76.43%
-54.08
-4944.68%
-1.07
-303.01%
-0.27
Purchase Of PPE
-12.75
+76.57%
-54.41
-4975.93%
-1.07
-303.01%
-0.27
Sale Of PPE
0.00
-100.00%
0.34
0.00
0.00
Capital Expenditure
-12.75
+76.57%
-54.41
-4975.93%
-1.07
-303.01%
-0.27
Net Investment Purchase And Sale
54.11
+132.84%
-164.78
-823.86%
22.76
0.00
Purchase Of Investment
-119.84
+50.79%
-243.51
0.00
0.00
Sale Of Investment
173.95
+120.95%
78.73
+245.85%
22.76
0.00
Net Business Purchase And Sale
—
0.00
-100.00%
2.70
—
Gain Loss On Sale Of Business
0.00
-100.00%
0.06
—
—
Net Other Investing Changes
-0.14
-87.50%
-0.07
-300.00%
-0.02
+0.00%
-0.02
Financing Cash Flow
10.30
-96.44%
289.38
+36764.33%
0.79
+1301.79%
0.06
Cash Flow From Continuing Financing Activities
10.30
-96.44%
289.38
+36764.33%
0.79
+1301.79%
0.06
Net Issuance Payments Of Debt
-0.05
-8.33%
-0.05
+29.41%
-0.07
—
Repayment Of Debt
-0.05
-8.33%
-0.05
+29.41%
-0.07
—
Long Term Debt Payments
-0.05
-8.33%
-0.05
+29.41%
-0.07
—
Net Long Term Debt Issuance
-0.05
-8.33%
-0.05
+29.41%
-0.07
—
Net Common Stock Issuance
9.99
-96.53%
288.18
+79070.33%
0.36
0.00
Cash Dividends Paid
—
—
—
0.00
Proceeds From Stock Option Exercised
0.37
-70.39%
1.25
+126.17%
0.55
+889.29%
0.06
Net Other Financing Charges
—
—
-0.07
—
Changes In Cash
-30.95
-159.34%
52.16
+543.73%
-11.76
-48.09%
-7.94
Beginning Cash Position
61.58
+553.72%
9.42
-55.51%
21.18
-66.92%
64.01
End Cash Position
30.63
-50.26%
61.58
+553.72%
9.42
-83.20%
56.07
Free Cash Flow
-95.23
-30.98%
-72.71
-91.41%
-37.98
-376.24%
-7.98
Interest Paid Supplemental Data
—
—
0.08
—
Amortization Of Securities
-2.72
-348.60%
-0.61
0.00
—
Common Stock Issuance
9.99
-96.53%
288.18
+79070.33%
0.36
0.00
Earnings Losses From Equity Investments
—
—
0.02
—
Issuance Of Capital Stock
9.99
-96.53%
288.18
+79070.33%
0.36
0.00
Preferred Stock Dividend Paid
—
—
—
0.00
Sale Of Business
—
0.00
-100.00%
2.70
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category